It hasn't finished the testing stage however I have lots of people in my family and friends now taking it. Hardly anyone is getting sick. This includes those that get sick a lot. They also don't take anything else and get over the cold fast.
I use to get sick a lot 5-6 times a year. Now I don't care if someone else is sick when I am around them etc.
Cold-fX is made by CV Technologies Inc.(TSX: CVQ), whose shares moved from the TSX Venture Exchange to the big board on March 22. The company has been developing natural remedies for more than a dozen years. But it has only been in the past two years that, due to an aggressive marketing campaign and several clinical trials that suggest Cold-fX actually works, that its fortunes have soared. During the year ended Sept. 30, sales revenue jumped nearly five times to $31.9 million, mainly on account of Cold-fX. According to marketing information firm ACNielsen, Cold-fX now ranks as the country's bestselling cold and flu remedy.
In 2004, the Edmonton-based company's net profit was a meagre $150,918. By last year, that figure had swelled to $10.1 million. Momentum continued in the first quarter of this fiscal year, with overall sales of $18.9 million and net earnings of $4.4 million. Not surprisingly, the stock has followed suit, rising from $1.77 last May to a high of $4.70 in November, although it has recently settled at $3.50. With 117 million shares(fully diluted), investors are now valuing the company at more than $400 million.
There are legions of ordinary people who don't get paid and still swear by the product. They insist that Cold-fX--a package of 18 capsules costs about $13.50--prevents colds or alleviates their symptoms. This word-of-mouth endorsement has become a key component of the company's marketing strategy. "The increasing sales of Cold-fX indicate many people find it works for them," says Jacqueline Shan, the company's president, CEO and chief scientific officer. "They make the economic judgment that the benefits of disease prevention outweigh the associated costs."
Shan says the company's ultimate goal is to obtain U.S. Food and Drug Administration approval to sell Cold-fX in the United States as an over-the-counter product, and that clinical trials to gain that approval will take at least three years and cost $20 million to $30 million.
Shan readily concedes, however, that more studies are needed. The company is now funding a much larger study involving 720 subjects in Toronto, Edmonton and Vancouver. The subjects are 65 and over and were previously vaccinated against flu. The purpose is to see whether Cold-fX can prevent laboratory-confirmed flu and cold viruses, and alleviate the severity and length of symptoms. The trial, which could have an impact on Cold-fX's future sales, is still in its early stages. No release date has been set.